Iqirvo PBC denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Iqirvo for PBC

Quantity limit (QL) denials for Iqirvo in primary biliary cholangitis usually mean Aetna's system has flagged that the prescription quantity or days' supply exceeds the amount authorized under Aetna's formulary management rules. This is frequently an administrative mismatch rather than a clinical disagreement — the prescribed quantity may reflect exactly what the FDA-approved prescribing label specifies, while Aetna's QL may be set differently in its system.

The most important first step is to confirm that the quantity prescribed by your physician matches the dosing regimen described in the FDA-approved prescribing information for Iqirvo. If it does, you have a strong argument that Aetna's quantity limit is inconsistent with the approved label.

## Your Federal Appeal Rights

• ERISA §503: Quantity limit denials are fully appealable under the full-and-fair review standard. You are entitled to know exactly what quantity limit is applied and why.
• ACA §2719 external review: Available after exhausting internal appeals. The external-review window is generally four months from the denial notice. Expedited review is available if delayed access to the correct quantity poses a risk to your health.
• Quantity limit exception: Most plans have a quantity limit exception process separate from (or alongside) a formal appeal — ask Aetna explicitly whether a QL exception request is available.

## Concrete Appeal Steps

1. Obtain the denial letter specifying the quantity limit that triggered the denial. 2. Download the FDA prescribing label for Iqirvo from FDA.gov — confirm the approved dosing regimen and typical dispensing quantity. 3. If the prescribed quantity matches the label-approved regimen, document that clearly in your appeal. 4. Have your prescriber provide a letter confirming the quantity is medically necessary and consistent with the approved label. 5. Request Aetna's written quantity limit policy for Iqirvo and challenge any limit that is inconsistent with the FDA-approved regimen.

## Documentation to Gather

• FDA prescribing label: The authoritative source for the approved dosing regimen — attach it and highlight the relevant dosing section.
• Prescription records: The prescription as written by your physician, showing the quantity and days' supply.
• Prescriber letter: Confirming that the quantity is required for continuous, uninterrupted treatment and is consistent with the approved label.
• Prior dispensing history: If you have received this medication before without a quantity limit issue, include that dispensing history.
• Clinical notes on disease management: Documenting why uninterrupted access to the full approved quantity is medically necessary — for example, gaps in treatment may allow disease progression.

## Criteria-Mapping Structure

Request Aetna's quantity limit criteria for Iqirvo. Map each requirement:

| Aetna Quantity Limit Basis | Your Counter-Evidence | |---|---| | [Stated limit or policy basis] | [FDA label dosing section; prescriber confirmation; prior dispensing records] |

If the limit conflicts with the FDA-approved label, state that conflict plainly and ask the external reviewer to apply the label as the authoritative clinical standard.